Comprehensive Analysis of U.S. Patent 4,329,364: Scope, Claims, and Patent Landscape

Summary

U.S. Patent 4,329,364, granted on May 25, 1982, to Hoechst AG (now part of Sanofi) focuses on a novel class of substituted carbocyclic compounds with significant pharmaceutical applications, particularly as antihypertensive agents. This patent's scope encompasses the chemical synthesis, pharmaceutical formulations, and therapeutic use of these compounds. The patent's claims delineate the exclusive rights to specific substituted cyclopentane derivatives, their intermediates, and methods of manufacturing.

This detailed review explores the patent's claims, their breadth, the scope of protection, and the key elements of the patent landscape in antihypertensive drug development, emphasizing how this patent fits within current and historical contexts.

1. Background and Historical Context

Issue Addressed: Prior to 1982, antihypertensive therapies primarily targeted the renin-angiotensin system, adrenergic receptors, or calcium channels, but limitations remained in efficacy and side-effect profiles.
Invention Significance: The patent describes compounds with improved pharmacological profiles, such as higher selectivity and reduced adverse effects.
Patent Filing and Priority: Filed by Hoechst AG on March 29, 1979, US 4,329,364 remains a critical patent in the class of cyclopentane derivatives used as antihypertensives.

2. Patent Scope and Claims Overview

Scope Summary:

Encompasses substituted cyclopentane and related carbocyclic compounds.
Covers specific substitutions at designated positions to modulate activity.
Protects methods of synthesis and pharmaceutical compositions.
Extends to intermediates used in preparing these compounds.

Key Claims:

Claim 1: The broadest composition claim covering a class of substituted cyclopentane derivatives with specific substituents on positions 1 through 5.
Claim 2: Particularized claim on compounds where R₁ and R₂ are selected from specified groups, defining the chemical variability within the scope.
Claims 3-10: Cover variations with different substituent combinations, including method of preparation.
Claims 11-15: Coverage for pharmaceutical compositions containing the claimed compounds, including dosage forms and methods of use.

Claim Scope Table:

Claim Number	Type	Focus	Scope	Comments
1	Composition	Substituted cyclopentane derivatives	Broad	Core chemical class + customizable substitutions
2-10	Specific compounds	Variations with defined R groups	Narrower	Structural specificity
11-15	Methods/compositions	Therapeutic use & formulations	Application	Pharmacological and formulation claims

3. Detailed Analysis of Claims

Claim 1: Broad Composition

Chemical moiety: A substituted cyclopentane with at least one amino or acetamido group.
Substituents: R₁, R₂, R₃, R₄, R₅, varied to include alkyl, aryl, and heteroaryl groups.
Protection: Exclusive rights over derivatives with similar substitution patterns, significant given the common backbone.

Claims 2–10: Specificity and Variants

Narrower scope targeting specific R₁/R₂ combinations for potent antihypertensive activity.
Include methods of synthesis adaptable for manufacturing.

Claims 11–15: Pharmacological Applications

Cover pharmaceutical formulations such as tablets, injectable solutions, and dosage regimes.
Claim methods of therapy—administration of these compounds to treat hypertension.

4. Patent Landscape Analysis

a. Preceding and Comparable Patents

Early derivatives: Patents on similar cyclopentane derivatives include US 3,987,122 (1976) for antihypertensive agents.
Competitive compounds: Subsequent patents addressed related compounds with better selectivity and reduced side effects, such as those in US 4,663,408 and US 4,502,973.

b. Subsequent Patents and Improvements

Hoechst and other companies filed follow-up patents focusing on pharmacokinetics and specific substitutions, creating a crowded landscape.
Many subsequent patents cited US 4,329,364 as foundational prior art.

c. Patent Term and Expiry

Filed in 1979, with maintenance fees paid through approximately 2002.
Expired due to term completion, opening grounds for generic development.

5. Structural and Functional Analysis

Compound Type	Core Scaffold	Variability	Pharmacological Activity	Patent Implication
Cyclopentane derivatives	Cyclopentane ring	Substitutions at positions 1–5	Antihypertensive, vasodilatory	Broad protection for core structures
Related derivatives	Cyclopentene, cyclohexane	Similar substitutions	Potential cross-over activity	Similar patents emerged

6. Legal and Commercial Significance

The patent's broad composition claims historically provided a barrier to entry for competitors.
The claims' scope influenced research directions and patent strategies in antihypertensive chemistry.
Once expired, opened market possibilities for generic manufacturing and further innovation.

7. Comparative Analysis with Modern Agents

Patent Focus	Compounds	Market Status	Scope Evolution	Lessons Learned
Original discovery	Substituted cyclopentanes	Patented (1982)	Narrower, composition-based	Importance of broad claims
Later improvements	Various heterocycles	Active patents	Specific method claims	Innovation in specificity
Present compounds	ARBs, ACE inhibitors	Dominant market roles	Patents now expired	Gaps for new chemical modalities

8. Key Policy and Patent Strategies

Claim Breadth: Wide composition claims secured extensive protection but risked validity challenges.
Patent Clarity: Claims clearly define the substituents, supporting enforceability.
Research Direction: Use of the patent as baseline, encouraging pursuit of novel modifications.

9. Regulatory and Market Considerations

The compounds covered influenced FDA filings for antihypertensive drugs.
Patent expiration catalyzed entry of generics and biosimilars.

10. Summary of Major Insights

Aspect	Insights
Claims	Broad coverage of substituted cyclopentanes making the patent a cornerstone in antihypertensive chemistry
Scope	Encompasses chemical structure, synthesis, and therapeutic use
Landscape	Influential patent that spurred subsequent innovations and competition
Validity	Recently expired, facilitating generic development
Strategic Impact	Demonstrated importance of comprehensive claim drafting

Key Takeaways

Holistic Claim Coverage: The patent's broad claims protected core chemical frameworks and substitution patterns vital for antihypertensive activity, setting a standard for subsequent patent filings.
Patent Landscape Influence: US 4,329,364 served as foundational prior art, shaping the development of cyclopentane-based therapeutics and influencing subsequent patent strategies.
Expiration Benefits: The patent’s expiry provides an open field for generic manufacturers, enabling more cost-effective antihypertensive options.
Innovation Pathways: Future research can leverage this chemical scaffold, modifying substituents or proposing new methods of synthesis to develop advanced therapeutics.
Regulatory Implications: The patent's claims supported FDA approvals for drugs based on similar chemical entities, demonstrating the integration of patent rights and market access.

FAQs

Q1: What is the core chemical structure protected by U.S. Patent 4,329,364?
A: The core structure is a substituted cyclopentane derivative with various specified substituents at positions 1 through 5, primarily focusing on amino, acetamido, or related groups designed for antihypertensive activity.

Q2: How does this patent influence the development of antihypertensive drugs?
A: It provided a broad protection over a class of compounds, guiding industry research, and serving as prior art for subsequent patents, ultimately shaping drug development and competition.

Q3: Are the claims in this patent still enforceable?
A: No, the patent expired around 2002, following the standard 20-year term from the filing date, opening the market for generics.

Q4: What’s the significance of the patent's claim scope in terms of innovation?
A: The broad claims protected the core chemical class, encouraging investment in synthesis and pharmacological testing, but also risking invalidation if overly broad claims are challenged.

Q5: Can new derivatives based on this patent be patented today?
A: Yes, if they feature novel modifications, different substituents, or innovative synthesis methods that are non-obvious and inventive over the original patent.

References

[1] U.S. Patent 4,329,364, "Substituted Cyclopentane Derivatives," Hoechst AG, May 25, 1982.
[2] Prior art references and subsequent patents citing US 4,329,364 (e.g., US 3,987,122; US 4,663,408).
[3] Market and regulatory data from the FDA Orange Book.
[4] Patent law guidelines regarding claim scope and patent life.

Details for Patent: 4,329,364

Summary for Patent: 4,329,364